R

Replimune Group
D

REPL

13.990
USD
-0.32
(-2.24%)
مغلق
حجم التداول
28,521
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
1,077,436,786
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AAPL
    AAPL
    -0.310
    (-0.13%)
    245.560 USD
    AMZN
    AMZN
    -6.305
    (-2.83%)
    216.495 USD
    C
    CLOV
    -0.08000
    (-1.79%)
    4.40000 USD
    CRM
    CRM
    -8.64
    (-2.71%)
    309.78 USD
    DIS
    DIS
    -1.910
    (-1.73%)
    108.670 USD
    GOOGL
    GOOGL
    -4.895
    (-2.65%)
    179.685 USD
    MSFT
    MSFT
    -7.96
    (-1.91%)
    408.15 USD
    NFLX
    NFLX
    -22.12
    (-2.16%)
    1,002.42 USD
    TSLA
    TSLA
    -16.87
    (-4.76%)
    337.50 USD
    المزيد
الأخبار
المقالات

العنوان: Replimune Group

القطاع: Healthcare
الصناعة: Biotechnology
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.